Drug Trial Radar · NCT06203821
Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
May 30, 2027
Study completion Sep 30, 2032
Sponsor
- Lead sponsor
- Aram HezelAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- NETRIS Pharma
- First posted
- Jan 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to investigate whether adding the study drug, NP137, to a patient's treatment regimen (before surgery and in combination with chemotherapy afterward) can alter the behavior of pancreatic cancer..
Conditions
- Pancreatic Cancer
Interventions
NP137Drug
NP137 for the Treatment of Resectable Pancreatic Cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determining if NP137 can shift the primary tumor MAK's Signature Epithelial-to-Mesenchymal Transition (EMT) Mean Score towards a more epithelial phenotypeTime frame: 3-5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Rochester
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.